NCT05321212View on ClinicalTrials.gov

Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

CompletedOBSERVATIONAL

Enrollment

108

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

January 2, 2019

Study Completion Date

March 2, 2019

Conditions

Carcinoma, Non-Small-Cell LungImmunotherapy

Trial Locations (2)

29000

CHIC de QUIMPER, Quimper

29609

CHRU de Brest, Brest

All Listed Sponsors

lead

University Hospital, Brest

OTHER

NCT05321212 - Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) | Biotech Hunter | Biotech Hunter